Ken Griffin Actinium Pharmaceuticals, Inc. Transaction History

Citadel Advisors LLC

$509 Billion
Q1 2024

A detailed history of Ken Griffin (Citadel Advisors LLC) transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Citadel Advisors LLC holds 23,900 shares of ATNM stock, worth $176,860. This represents 0.0% of its overall portfolio holdings.

Number of Shares

23,900

Previous 18,000 32.78%

Holding current value

$176,860

Previous $91,000 105.49%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	BUY	$5.0 - $9.2 $378,535 - $696,504	75,707 Added 233.61%	108,115 $846,000
Q4 2023 Feb 14, 2024	SELL	$4.02 - $6.08 $147,461 - $223,026	-36,682 Reduced 53.09%	32,408 $164,000
Q3 2023 Nov 14, 2023	SELL	$5.91 - $7.37 $608,611 - $758,962	-102,980 Reduced 59.85%	69,090 $409,000
Q2 2023 Aug 14, 2023	BUY	$7.15 - $9.39 $737,422 - $968,447	103,136 Added 149.62%	172,070 $1.28 Million
Q1 2023 May 15, 2023	SELL	$8.51 - $14.26 $446,672 - $748,478	-52,488 Reduced 43.23%	68,934 $651,000

Q4 2022 Feb 14, 2023	BUY	$9.71 - $12.51 $779,848 - $1 Million	80,314 Added 195.37%	121,422 $1.29 Million
Q3 2022 Nov 14, 2022	SELL	$4.81 - $8.48 $59,451 - $104,812	-12,360 Reduced 23.12%	41,108 $303,000
Q2 2022 Aug 15, 2022	BUY	$4.71 - $7.11 $135,638 - $204,753	28,798 Added 116.73%	53,468 $257,000
Q1 2022 May 16, 2022	BUY	$4.57 - $6.4 $62,467 - $87,481	13,669 Added 124.25%	24,670 $126,000
Q3 2021 Nov 15, 2021	SELL	$5.76 - $9.67 $204,399 - $343,149	-35,486 Reduced 76.34%	11,001 $98,000
Q4 2020 Feb 16, 2021	BUY	$7.8 - $12.64 $238,110 - $385,861	30,527 Added 191.27%	46,487 $363,000
Q3 2020 Nov 16, 2020	BUY	$7.26 - $18.0 $115,869 - $287,280	15,960 New	15,960 $155,000

Others Institutions Holding ATNM

# of Institutions

Shares Held

6.65M

Call Options Held

369K

Put Options Held

148K

View Full List

About Actinium Pharmaceuticals, Inc.

Ticker ATNM
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 25,184,700
Market Cap $186M
Description
Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...

More about ATNM

Track Ken Griffin's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Account